Future operations in 2020

Organic cell background

Happy new year to all, we hope the new year brings new opportunities and progress in all aspects of your life.

As many are aware, the third quarter of 2019 has been negative for the SARMs, Nootropics and Peptide industry. China has outright banned the production and sale of SARMs. Despite what you may have heard, all SARMs and their API Powder form are produced in China. It’s not that other countries, including the west and prospective countries such as India don’t have the capacity to synthesise this class of chemicals, it’s the regulation and public image of the manufacturers that are the main issues.

The quality of the product has been good to date, the main issues arise from trading companies not maintaining their own QC or deliberately defrauding their customers. 3 main companies were supplying most vendors in the industry, and have been continuously tested by various different vendors and have all been positive, averaging purity reports of over 99%.

As a result of this ban, the following issues are arising:

  1. Lack of sources
  2. Diminished quality
  3. Price increase

We have been working with the same supplier for the vast majority of our 3 year operation, and the quality has never come into question, and our final products reflect this. Because SARMs are going to become an “underground” substance in China, the risk of being supplied with fake or potentially dangerous compounds has increased exponentially. Prices have already increased dramatically, Ostarine has increased by an average of 400% per gram.

There are also many individuals who will take advantage of this lack of supply by either sending highly cut APIs or totally fake batches. Each batch would require comprehensive testing, which is extremely expensive and combined with the raw price increase, will see a sharp increase in retail prices. We are prepared to invest in the necessary analytical equipment, but because of the difficulty in obtaining card processing and increasing pressure from authorities, it’s not a viable investment at the moment.

Because we decided to operate as registered company, we take on responsibility to meet label claims and legislation applies to us, while as an individual seller the laws are more unclear. Currently, we have not been able to identify a new supplier who can meet our standards. We are relying on our remaining stock, after this, we can’t estimate when we will be able stock SARMs once more. We’re going to closely monitor the news in the industry, there have been rumours about API manufactures in India stepping in, but the Pharmaceutical industry is one of India’s biggest industries, and it’s doubtful that regulators will allow the PR of the industry to come under fire from PED production.

On a global scale, Australia has outright banned SARMs, the US is following and the UK is preparing to release a report into P/IED use, which will likely result in a blanket ban on anabolic substances, similar to the Psychoactive Substances Act, which saw an entire industry collapse overnight.

The Food Standards agency has also issued guidance on SARMs, which recommends enforcement against any supplier selling human consumption forms of SARMs. Because of the drop in income since our CC processing and cash flow being held by payment processors, once our stock is sold it’s likely we will go dormant until there can be positive news in this industry.

To all our Customers. Thank you for supporting us, we hope you have achieved your research goals.

If you haven’t had a positive experience, we’re sorry – there are occasions where we’ve had to take action that Customers are not happy with, but throughout our operation we’ve always taken the financial loss of customs seizures, breakages, peace of mind replacements, but there are limits every company must set, and with the unknown nature of SARMs, it’s impossible to guarantee what effects may or may not occur.